Lifecore Biomedical (LFCR) Earnings Date & Reports

Key Takeaways

• Lifecore Biomedical reported total revenue of $25.3 million for its third quarter of 2026, down 18.6% from $31.1 million a year earlier and slightly below the consensus estimate of roughly $25.6 million.
• The company posted a GAAP net loss of $40.1 million, or $1.08 per diluted share, versus a $10.0 million loss ($0.29 per share) in the prior-year quarter, missing consensus expectations of about a $0.30 per-share loss.
• The wider loss was driven largely by a non-cash increase in the fair value of a debt derivative liability, rather than an operational deterioration.
• Adjusted EBITDA rose to $4.0 million from $3.1 million a year earlier, reflecting ongoing cost discipline and efficiency initiatives.
• Nine-month revenue totaled $82.7 million, down 21.8% year over year, while management highlighted multiple new business wins strengthening its commercial and development pipeline.
• For additional context, review Lifecore's Major News, Today's Price Move, Price Targets, and Forecast on the company's dedicated pages.
• Explore Trending AI Robots to see how AI-driven trading strategies are approaching stocks like LFCR.

Earnings Context and Why It Matters

Lifecore Biomedical is a fully integrated CDMO (contract development and manufacturing organization) that develops and manufactures sterile injectable products and premium hyaluronic acid, or HA. Its quarterly results matter because the company is in the middle of a turnaround, investing in capacity while working to convert a growing development pipeline into commercial revenue. The third-quarter report tests whether cost discipline and new program wins can offset a top-line decline tied to a prior customer loss and HA inventory normalization. For investors, the spread between a widening GAAP (Generally Accepted Accounting Principles) loss and improving adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) is a key signal of how much of the loss is non-cash rather than operational.

Reported Results

For the third quarter ended September 30, 2026, Lifecore Biomedical reported total revenue of $25.3 million, a decline of 18.6% from $31.1 million in the prior-year period. The figure came in slightly below the consensus estimate of approximately $25.6 million.

The company's GAAP net loss widened to $40.1 million, or $1.08 per diluted share, compared with a net loss of $10.0 million, or $0.29 per share, a year ago. The result fell short of analyst expectations of roughly a $0.30 per-share loss. Management attributed much of the larger reported loss to a non-cash charge related to the change in fair value of a debt derivative liability, which is excluded from the company's adjusted measures.

On an adjusted basis, adjusted EBITDA rose to $4.0 million from $3.1 million in the prior-year quarter. Gross profit was $6.8 million, down from $7.8 million, while gross margin narrowed. For the first nine months of 2026, revenue was $82.7 million (down 21.8%) and adjusted EBITDA was $13.6 million, compared with $21.1 million in the same period a year earlier. The company ended the quarter with approximately $38.0 million in total liquidity, including $23.0 million in cash and $15.0 million of revolving credit availability.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following names like Lifecore Biomedical, the AI Screener offers a structured way to surface relevant signals and monitor changing conditions across the sector.

Market Reaction and Investor Sentiment

Investor sentiment around Lifecore Biomedical heading into the report reflected caution over a top-line decline tied to customer concentration and HA inventory normalization. The third-quarter results did little to resolve that tension: revenue missed modestly, and the headline GAAP loss was significantly wider than expected, primarily because of a non-cash derivative charge.

At the same time, the improvement in adjusted EBITDA and management's emphasis on new business wins provided a more constructive underlying narrative. The divergence between the reported GAAP loss and the stronger adjusted metric underscores the importance for investors of looking past non-cash items when evaluating the company's operating trajectory. Persistent concerns around customer concentration, liquidity, and the timing of pipeline conversion remain central to how the market interprets these results.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors will be watching several factors closely. The most important is whether Lifecore can hold to its full-year 2026 guidance, which calls for total revenue of roughly $120 million to $125 million and adjusted EBITDA of $20.5 million to $25 million. Meeting those targets will require a meaningful step-up in revenue during the fourth quarter, consistent with management's prior comments that orders were weighted toward the back half of the year.

Pipeline conversion is another key watch item. Lifecore has pointed to multiple new program wins, including commercial site transfers and late-stage development opportunities. The pace at which these programs move from development to commercial manufacturing will determine whether the company can rebuild revenue growth and improve capacity utilization over time.

Cost and liquidity trends also deserve attention. Management has been reducing selling, general, and administrative expenses and implementing efficiency projects, and the company began paying a portion of its debt service in cash rather than in-kind. Sustained progress on free cash flow and working capital will be important given the company's capital structure.

Finally, the company's long-term goals, including a 12% revenue CAGR (compound annual growth rate) and adjusted EBITDA margins above 25% by the end of 2029, will remain a reference point for investors assessing whether the current restructuring is translating into durable, profitable growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations